B. Lacour, Childhood cancer survival in France, Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. ECP, vol.23, pp.449-457, 2000.
URL : https://hal.archives-ouvertes.fr/hal-01801206

, Institut National du Cancer (INCA), 2014.

I. Sultan, Soft tissue sarcomas in the first year of life, Eur. J. Cancer Oxf. Engl, vol.46, pp.2449-2456, 1990.

T. E. Lobe, Neonatal rhabdomyosarcoma: the IRS experience, J. Pediatr. Surg, vol.29, pp.1167-1170, 1994.
DOI : 10.1016/0022-3468(94)90302-6

D. Kamil, Spectrum and outcome of prenatally diagnosed fetal tumors, Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol, vol.31, pp.296-302, 2008.
DOI : 10.1002/uog.5260

N. J. Sebire and E. Jauniaux, Fetal and placental malignancies: prenatal diagnosis and management
DOI : 10.1002/uog.6246

, Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol, vol.33, pp.235-244, 2009.

D. Orbach, Neonatal cancer. Lancet Oncol, vol.14, pp.609-620, 2013.

S. E. Lipshultz, V. I. Franco, and T. R. Cochran, Cardiotoxicity in childhood cancer survivors: a problem with long-term consequences in need of early detection and prevention. Pediatr, Blood Cancer, vol.60, pp.1395-1396, 2013.

S. L. Mcgovern and A. Mahajan, Progress in radiotherapy for pediatric sarcomas, Curr. Oncol. Rep, vol.14, pp.320-326, 2012.

C. Arndt, Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.22, pp.1894-1901, 2004.

G. J. Veal and A. V. Boddy, Chemotherapy in newborns and preterm babies, Semin. Fetal. Neonatal Med, vol.17, pp.243-248, 2012.

G. L. Kearns, Developmental pharmacology--drug disposition, action, and therapy in infants and children, N. Engl. J. Med, vol.349, pp.1157-1167, 2003.

H. Van-den-berg, J. N. Van-den-anker, and J. H. Beijnen, Cytostatic drugs in infants: a review on pharmacokinetic data in infants, Cancer Treat. Rev, vol.38, pp.3-26, 2012.

C. Rodriguez-antona and M. Ingelman-sundberg, Cytochrome P450 pharmacogenetics and cancer, Oncogene, vol.25, pp.1679-1691, 2006.

G. J. Veal, Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens, Cancer Chemother. Pharmacol, vol.77, pp.685-692, 2016.

D. Orbach, Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, pp.4363-4371, 2005.

R. Alaggio, G. Bisogno, A. Rosato, V. Ninfo, and C. M. Coffin, Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature, Hum. Pathol, vol.40, pp.1600-1610, 2009.

S. R. Knezevich, D. E. Mcfadden, W. Tao, J. F. Lim, and P. H. Sorensen, A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma, Nat. Genet, vol.18, pp.184-187, 1998.

A. J. Church, Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy, Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc, vol.31, pp.463-473, 2018.

D. Orbach, Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience, Eur. J. Cancer Oxf. Engl, vol.57, pp.1-9, 1990.

E. Mccahon, P. H. Sorensen, J. H. Davis, P. C. Rogers, and K. R. Schultz, Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy, Med. Pediatr. Oncol, vol.40, pp.288-292, 2003.

G. Surico, Chemotherapy alone for the treatment of congenital fibrosarcoma: is surgery always needed?, Med. Pediatr. Oncol, vol.40, pp.268-270, 2003.

T. W. Laetsch, Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study, Lancet Oncol, issue.18, pp.30119-30119, 2018.

A. P. Stout, Rhabdomyosarcoma of the Skeletal Muscles, Ann. Surg, vol.123, pp.447-472, 1946.

P. N. Tonin, H. Scrable, H. Shimada, and W. K. Cavenee, Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development, Cancer Res, vol.51, pp.5100-5106, 1991.

V. D. Soleimani and M. Rudnicki, New insights into the origin and the genetic basis of rhabdomyosarcomas, Cancer Cell, vol.19, pp.157-159, 2011.

D. S. Hawkins, A. A. Gupta, and E. R. Rudzinski, What is new in the biology and treatment of pediatric rhabdomyosarcoma?, Curr. Opin. Pediatr, vol.26, pp.50-56, 2014.

E. R. Rudzinski, The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group, Arch. Pathol. Lab. Med, vol.139, pp.1281-1287, 2015.

P. H. Sorensen, PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.20, pp.2672-2679, 2002.

F. G. Barr, Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group

, J. Mol. Diagn. JMD, vol.8, pp.202-208, 2006.

E. R. Rudzinski, Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr, Blood Cancer, vol.64, 2017.

X. Sun, Advances in Molecular and Cellular Biology, vol.2015, p.232010, 2015.

Y. Ren, Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations, Cancer Res, vol.68, pp.6587-6597, 2008.

S. J. Rodig and G. I. Shapiro, Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases, Curr. Opin. Investig. Drugs Lond. Engl, vol.11, pp.1477-1490, 2000.

E. Missiaglia, Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development, Genes. Chromosomes Cancer, vol.48, pp.455-467, 2009.

J. A. Bridge, Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes, Genes. Chromosomes Cancer, vol.33, pp.310-321, 2002.

M. Goldstein, I. Meller, J. Issakov, and A. Orr-urtreger, Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors, vol.8, pp.332-343, 2006.

J. F. Shern, Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors, Cancer Discov, vol.4, pp.216-231, 2014.

M. C. Chiles, Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group

, Dev. Pathol. Off. J. Soc. Pediatr. Pathol. Paediatr. Pathol. Soc, vol.8, p.141, 2005.

R. Croes, Adult sclerosing rhabdomyosarcoma: cytogenetic link with embryonal rhabdomyosarcoma, Virchows Arch. Int. J. Pathol, vol.446, pp.64-67, 2005.

H. Hosoi, A novel PAX3 rearrangement in embryonal rhabdomyosarcoma, Cancer Genet. Cytogenet, vol.189, pp.98-104, 2009.

S. J. Xia, J. G. Pressey, and F. G. Barr, Molecular pathogenesis of rhabdomyosarcoma, Cancer Biol. Ther, vol.1, pp.97-104, 2002.

I. Sultan, I. Qaddoumi, S. Yaser, C. Rodriguez-galindo, and A. Ferrari, Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, pp.3391-3397, 2009.

D. Williamson, Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.2151-2158, 2010.

B. Brennan, Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatr, Blood Cancer, vol.65, 2018.

N. Yasui, Clinicopathologic analysis of spindle cell/sclerosing rhabdomyosarcoma. Pediatr, Blood Cancer, vol.62, pp.1011-1016, 2015.

V. Y. Jo and C. D. Fletcher, WHO classification of soft tissue tumours: an update based on the, Pathology (Phila.), vol.46, pp.95-104, 2013.

Z. Zhao, Spindle cell/sclerosing rhabdomyosarcoma: case series from a single institution emphasizing morphology, immunohistochemistry and follow-up, Int. J. Clin. Exp. Pathol, vol.8, pp.13814-13820, 2015.

T. Mentzel and D. Katenkamp, Sclerosing, pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases, Virchows Arch. Int. J. Pathol, vol.436, pp.305-311, 2000.

B. Rekhi, P. Upadhyay, M. P. Ramteke, and A. Dutt, MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes, Mod. Pathol. Off. J. U. S. Can. Acad, 2016.

N. P. Agaram, Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis, Genes. Chromosomes Cancer, vol.53, pp.779-787, 2014.

F. B. Ruymann, Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee (representing the Children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom Children's Cancer Study Group, and the Pediatric Intergroup Statistical Center, Med. Pediatr. Oncol, vol.16, pp.33-39, 1988.

N. M. Archer, An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome? Pediatr, Blood Cancer, vol.63, pp.196-201, 2016.

A. Ray and W. W. Huh, Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas, Curr. Oncol. Rep, vol.14, pp.311-319, 2012.

M. C. Stevens, Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, pp.2618-2628, 2005.

O. Oberlin, Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.30, pp.2457-2465, 2012.

L. Yang, T. Takimoto, and J. Fujimoto, Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma, BMC Cancer, vol.14, p.654, 2014.

W. Crist, The Third Intergroup Rhabdomyosarcoma Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.13, pp.610-630, 1995.

D. Joshi, Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr, Blood Cancer, vol.42, pp.64-73, 2004.

S. X. Skapek, PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr, Blood Cancer, vol.60, pp.1411-1417, 2013.

A. O. Cavazzana, Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma, Am. J. Surg. Pathol, vol.16, pp.229-235, 1992.

I. Leuschner, Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study, Am. J. Surg. Pathol, vol.17, pp.221-230, 1993.

A. Ferrari, Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group, Cancer, vol.97, pp.2597-2604, 2003.

S. Malempati, Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group, Cancer, vol.117, pp.3493-3501, 2011.

A. Meloni-ehrig, Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma, Cancer Genet. Cytogenet, vol.191, pp.43-45, 2009.

J. M. Mosquera, Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma, Genes. Chromosomes Cancer, vol.52, pp.538-550, 2013.

R. Alaggio, A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases, Am. J. Surg. Pathol, vol.40, pp.224-235, 2016.

C. Rodary, F. Flamant, and S. S. Donaldson, An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP), Med. Pediatr. Oncol, vol.17, pp.210-215, 1989.

W. Lawrence, E. A. Gehan, D. M. Hays, M. Beltangady, and H. M. Maurer, Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II), J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.5, pp.46-54, 1987.

D. Kim, TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions, Genome Biol, vol.14, p.36, 2013.

A. Dobin, STAR: ultrafast universal RNA-seq aligner, Bioinforma. Oxf. Engl, vol.29, pp.15-21, 2013.

A. Mcpherson, deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data, PLoS Comput. Biol, vol.7, p.1001138, 2011.

B. Haas, STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq, p.120295, 2017.

D. Nicorici, FusionCatcher -a tool for finding somatic fusion genes in paired-end RNA-sequencing data, p.11650, 2014.

N. L. Bray, H. Pimentel, P. Melsted, and L. Pachter, Near-optimal probabilistic RNA-seq quantification, Nat. Biotechnol, vol.34, pp.525-527, 2016.

. The-r-core, The R Project for Statistical Computing, p.5, 2016.

J. L. Van-nostrand, Inappropriate p53 activation during development induces features of CHARGE syndrome, Nature, vol.514, pp.228-232, 2014.

J. Sumegi, Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family, Genes. Chromosomes Cancer, vol.49, pp.224-236, 2010.

S. Watson, Transcriptomic definition of molecular subgroups of small round cell sarcomas, J. Pathol, vol.245, pp.29-40, 2018.

A. Y. Minn, Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, pp.4228-4232, 2010.

T. Maeda, D. L. Chapman, and A. F. Stewart, Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation, J. Biol. Chem, vol.277, pp.48889-48898, 2002.

S. Günther, M. Mielcarek, M. Krüger, and T. Braun, VITO-1 is an essential cofactor of TEF1-dependent muscle-specific gene regulation, Nucleic Acids Res, vol.32, pp.791-802, 2004.

T. Yoshida, MCAT elements and the TEF-1 family of transcription factors in muscle development and disease, Arterioscler. Thromb. Vasc. Biol, vol.28, pp.8-17, 2008.

H. Yoshida, PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells, Oncogene, vol.33, pp.5601-5608, 2014.

T. J. Fete and M. Fete, International research symposium on Goltz syndrome, Am. J. Med. Genet. C Semin. Med. Genet, vol.172, pp.3-6, 2016.

D. Pavlick, Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr, Blood Cancer, vol.64, 2017.

N. P. Agaram, Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors, Am. J. Surg. Pathol, vol.40, pp.1407-1416, 2016.

J. L. Davis, Infantile NTRK-associated Mesenchymal Tumors, Pediatr. Dev. Pathol. Off. J. Soc. Pediatr. Pathol. Paediatr. Pathol. Soc, vol.21, pp.68-78, 2018.

V. Wong, Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib, J. Natl. Cancer Inst, vol.108, 2016.

Y. Kao, Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma, Am. J. Surg. Pathol, vol.42, pp.28-38, 2018.

F. Haller, Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern, J. Pathol, vol.238, pp.700-710, 2016.

R. C. Doebele, An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101, Cancer Discov, vol.5, pp.1049-1057, 2015.

A. Amatu, A. Sartore-bianchi, and S. Siena, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, ESMO Open, vol.1, p.23, 2016.

T. Mentzel, Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues

. Pathol, , vol.31, pp.91-96, 2010.

, Rhabdomyosarcoma in newborn and infants: an integrative clinical, histological and